{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:18:27Z","timestamp":1790259507483,"version":"4.1.0"},"reference-count":103,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T00:00:00Z","timestamp":1621036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Over the past years, the identification of genetic alterations in oncogenic drivers in non-small cell lung cancer (NSCLC) has significantly and favorably transformed the outcome of patients who can benefit from targeted therapies such as tyrosine kinase inhibitors. Among these genetic alterations, anaplastic lymphoma kinase (ALK) rearrangements were discovered in 2007 and are present in 3\u20135% of patients with NSCLC. In addition, radiotherapy remains one of the cornerstones of NSCLC treatment. Moreover, improvements in the field of radiotherapy with the use of hypofractionated or ablative stereotactic radiotherapy have led to a better outcome for localized or oligometastatic NSCLC. To date, the effects of the combination of ALK inhibitors and radiotherapy are unclear in terms of safety and efficacy but could potently improve treatment. In this manuscript, we provide a clinical and preclinical overview of combining radiation therapy with ALK inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.<\/jats:p>","DOI":"10.3390\/cancers13102394","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T23:17:16Z","timestamp":1621207036000},"page":"2394","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview"],"prefix":"10.3390","volume":"13","author":[{"given":"Delphine","family":"Antoni","sequence":"first","affiliation":[{"name":"Paul Strauss Comprehensive Cancer Center, Radiobiology Laboratory, Institut de Canc\u00e9rologie Strasbourg Europe (ICANS), Strasbourg University, UNICANCER, 67000 Strasbourg, France"},{"name":"Department of Radiotherapy, ICANS, Institut de Canc\u00e9rologie Strasbourg Europe, 17 rue Albert Calmette, CEDEX, 67200 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9612-5806","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Burckel","sequence":"additional","affiliation":[{"name":"Paul Strauss Comprehensive Cancer Center, Radiobiology Laboratory, Institut de Canc\u00e9rologie Strasbourg Europe (ICANS), Strasbourg University, UNICANCER, 67000 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Noel","sequence":"additional","affiliation":[{"name":"Paul Strauss Comprehensive Cancer Center, Radiobiology Laboratory, Institut de Canc\u00e9rologie Strasbourg Europe (ICANS), Strasbourg University, UNICANCER, 67000 Strasbourg, France"},{"name":"Department of Radiotherapy, ICANS, Institut de Canc\u00e9rologie Strasbourg Europe, 17 rue Albert Calmette, CEDEX, 67200 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: A pooled analysis of two randomised trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ijrobp.2007.10.053","article-title":"Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer","volume":"70","author":"Lagerwaard","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.lungcan.2018.11.013","article-title":"Stereotactic body radiation therapy for stage I non-small cell lung carcinomas: Moderate hypofractionation optimizes outcome","volume":"126","author":"Menoux","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/j.canrad.2016.07.009","article-title":"Radioth\u00e9rapie des cancers primitifs du poumon","volume":"20","author":"Giraud","year":"2016","journal-title":"Cancer Radioth\u00e9r."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.canrad.2014.05.002","article-title":"Radioth\u00e9rapie en conditions st\u00e9r\u00e9otaxiques des tumeurs bronchopulmonaires [Stereotactic ablative irradiation for lung cancer]","volume":"18","author":"Antoni","year":"2014","journal-title":"Cancer Radioth\u00e9r."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/JTO.0b013e31825493eb","article-title":"Development of PI3K\/AKT\/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer","volume":"7","author":"Papadimitrakopoulou","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/EDBK_176251","article-title":"Managing Resistance to EFGR- and ALK-Targeted Therapies","volume":"Volume 37","author":"Lovly","year":"2017","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","article-title":"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors","volume":"71","author":"Sasaki","year":"2011","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1747-0285.2011.01239.x","article-title":"Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen","volume":"78","author":"Zhang","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ccell.2014.09.019","article-title":"ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma","volume":"26","author":"Bresler","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"a002550","DOI":"10.1101\/mcs.a002550","article-title":"Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib","volume":"4","author":"Guan","year":"2018","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/JTO.0000000000000094","article-title":"Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802\/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib","volume":"9","author":"Ou","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"v602","DOI":"10.1093\/annonc\/mdz260.006","article-title":"Final PFS, updated OS and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC","volume":"30","author":"Mok","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.05.019","article-title":"Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria","volume":"82","author":"Gandhi","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2016.68.4639","article-title":"Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer","volume":"34","author":"Gadgeel","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","article-title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study","volume":"29","author":"Gadgeel","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study","volume":"14","author":"Camidge","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): An open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mamesaya, N., Nakashima, K., Naito, T., Nakajima, T., Endo, M., and Takahashi, T. (2017). ALK-rearranged lung squamous cell carcinoma responding to alectinib: A case report and review of the literature. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3468-1"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_32","unstructured":"Couraud, S., Westeel, V., Ranchon, F., Toffart, A.-C., and Souquet, P.-J. (2021, March 01). On behalf of the editing committee of Auvergne Rh\u00f4ne-AlpesGuidelines in Thoracic Oncology. [Guidelines on Non-Small Cells Lung Cancer: 2021Update]. ARISTOT 2021 [French]. Available online: http:\/\/referentiels-aristot.com\/."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1073\/pnas.1420785112","article-title":"PF-06463922 is a potent and selective next-generation ROS1\/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations","volume":"112","author":"Zou","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial","volume":"35","author":"Kim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: An international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","article-title":"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors","volume":"363","author":"Choi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.ejca.2010.04.002","article-title":"The biology and treatment of EML4-ALK non-small cell lung cancer","volume":"46","author":"Sasaki","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1200\/JCO.2009.23.6661","article-title":"EML4-ALK: Honing in on a new target in non-small-cell lung cancer","volume":"27","author":"Horn","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-11-3260","article-title":"Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants","volume":"18","author":"Heuckmann","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","article-title":"Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer","volume":"34","author":"Yoshida","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ccell.2015.02.005","article-title":"A functional landscape of resistance to ALK inhibition in lung cancer","volume":"27","author":"Wilson","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"120ra17","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1126\/science.1254721","article-title":"Patient-derived models of acquired resistance can identify effective drug combinations for cancer","volume":"346","author":"Crystal","year":"2014","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3892\/ijo.2014.2574","article-title":"Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition","volume":"45","author":"Kogita","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1535-6108(04)00115-1","article-title":"Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules","volume":"5","author":"Moeller","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrc3007","article-title":"Strategies to improve radiotherapy with targeted drugs","volume":"11","author":"Begg","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2013.11.010","article-title":"Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib","volume":"88","author":"Gan","year":"2014","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer","volume":"7","author":"Weickhardt","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_52","first-page":"434","article-title":"Radiotherapy and targeted therapy\/immunotherapy","volume":"20","author":"Antoni","year":"2016","journal-title":"Cancer Radiother. J. Soc. Fr. Radiother. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fonc.2013.00113","article-title":"DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy","volume":"3","author":"Mladenov","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2004.03.005","article-title":"Role of cell cycle in mediating sensitivity to radiotherapy","volume":"59","author":"Pawlik","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2214\/AJR.19.21982","article-title":"Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer","volume":"214","author":"Mendoza","year":"2020","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_56","unstructured":"(2021, March 01). Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT01822496?cond=NCT01822496&draw=2&rank=1."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S1470-2045(15)00013-3","article-title":"Targeting brain metastases in ALK-rearranged non-small-cell lung cancer","volume":"16","author":"Zhang","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10585-020-10026-2","article-title":"A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation","volume":"37","author":"Yang","year":"2020","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1093\/annonc\/mdx408","article-title":"Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: Toxicities and efficacy","volume":"28","author":"Tallet","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_60","first-page":"463","article-title":"Role of radiation therapy in brain metastases management","volume":"24","author":"Dhermain","year":"2020","journal-title":"Cancer Radiother. J. Soc. Fr. Radiother. Oncol."},{"key":"ref_61","first-page":"159","article-title":"Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience","volume":"32","author":"Borghetti","year":"2018","journal-title":"In Vivo"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study","volume":"37","author":"Gomez","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1535-7163.MCT-12-0868","article-title":"ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK","volume":"12","author":"Sun","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3892\/or.2012.2198","article-title":"Effect of PF-02341066 and radiation on non-small cell lung cancer cells","volume":"29","author":"Tumati","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.radonc.2014.12.009","article-title":"Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer","volume":"114","author":"Dai","year":"2015","journal-title":"Radiother. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-017-0947-0","article-title":"Oncogene addiction and radiation oncology: Effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC","volume":"13","author":"Dai","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1073\/pnas.1019559108","article-title":"Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK","volume":"108","author":"Katayama","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.21873\/anticanres.14497","article-title":"ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer","volume":"40","author":"Fleschutz","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2307\/3579199","article-title":"Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells","volume":"145","author":"Fleschutz","year":"1996","journal-title":"Radiat. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1158\/0008-5472.CAN-04-3547","article-title":"Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)","volume":"65","author":"Chinnaiyan","year":"2005","journal-title":"Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.canlet.2016.02.009","article-title":"Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer","volume":"374","author":"Kang","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbi.2018.02.018","article-title":"5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells","volume":"284","author":"Han","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd3801","article-title":"The determination and interpretation of the therapeutic index in drug development","volume":"11","author":"Muller","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/ncponc0744","article-title":"Exploitable mechanisms for combining drugs with radiation: Concepts, achievements and future directions","volume":"4","author":"Bentzen","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Ducray, S.P., Natarajan, K., Garland, G.D., Turner, S.D., and Egger, G. (2019). The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis. Cancers, 11.","DOI":"10.3390\/cancers11081074"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrm1202","article-title":"Mechanism and regulation of human non-homologous DNA end-joining","volume":"4","author":"Lieber","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-05-2454","article-title":"Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair","volume":"12","author":"Toulany","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1158\/0008-5472.CAN-07-0242","article-title":"Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma","volume":"67","author":"Das","year":"2007","journal-title":"Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0360-3016(02)02848-1","article-title":"Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer","volume":"53","author":"Koukourakis","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_82","first-page":"2911","article-title":"Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer","volume":"61","author":"Aebersold","year":"2001","journal-title":"Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijrobp.2013.03.013","article-title":"Radiobiology of stereotactic body radiation therapy\/stereotactic radiosurgery and the linear-quadratic model","volume":"87","author":"Song","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1097\/JTO.0000000000000113","article-title":"Crizotinib can overcome acquired resistance to CH5424802: Is amplification of the MET gene a key factor?","volume":"9","author":"Gouji","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"8823","DOI":"10.18632\/oncotarget.24260","article-title":"ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer","volume":"9","author":"Pilling","year":"2018","journal-title":"Oncotarget"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.tranon.2018.09.013","article-title":"MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report","volume":"12","author":"Rihawi","year":"2019","journal-title":"Transl. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Network TCGAR (2013). Corrigendum: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 494, 506.","DOI":"10.1038\/nature11903"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2012.06.001","article-title":"The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma","volume":"22","author":"Berry","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1242\/dmm.024448","article-title":"The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN","volume":"9","author":"Guan","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1158\/1078-0432.CCR-09-2660","article-title":"Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification","volume":"16","author":"Kumps","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41408-020-0320-7","article-title":"\u201cDirect to Drug\u201d screening as a precision medicine tool in multiple myeloma","volume":"10","author":"Kumps","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-08-1845","article-title":"IRF4: Immunity. Malignancy! Therapy?","volume":"15","author":"Shaffer","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1593\/neo.121258","article-title":"c-Myc suppression of DNA double-strand break repair","volume":"14","author":"Li","year":"2012","journal-title":"Neoplasia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11010-015-2422-2","article-title":"The involvement of c-Myc in the DNA double-strand break repair via regulating radiation-induced phosphorylation of ATM and DNA-PKcs activity","volume":"406","author":"Cui","year":"2015","journal-title":"Mol. Cell. Biochem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","article-title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): A multicentre, international, randomised, open-label phase 3 trial","volume":"18","author":"Brahmer","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e000970","DOI":"10.1136\/jitc-2020-000970","article-title":"Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer","volume":"8","author":"Pyo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/s41467-019-09415-3","article-title":"Crizotinib-induced immunogenic cell death in non-small cell lung cancer","volume":"10","author":"Liu","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1596652","DOI":"10.1080\/2162402X.2019.1596652","article-title":"Crizotinib\u2014A tyrosine kinase inhibitor that stimulates immunogenic cell death","volume":"8","author":"Liu","year":"2019","journal-title":"OncoImmunology"},{"key":"ref_100","first-page":"2365","article-title":"Effects of Corynebacterium granulosum on weight and histology of lymphoid organs, response to mitogens, skin allografts, and a syngeneic fibrosarcoma in mice","volume":"35","author":"Milas","year":"1975","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S1470-2045(09)70082-8","article-title":"Systemic effects of local radiotherapy","volume":"10","author":"Formenti","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_102","first-page":"244","article-title":"Immunotherapy and radiotherapy","volume":"21","author":"Bockel","year":"2017","journal-title":"Cancer Radiother. J. Soc. Fr. Radiother. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation; radiobiology or medicine?","volume":"26","author":"Mole","year":"1953","journal-title":"Br. J. Radiol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/10\/2394\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:01:55Z","timestamp":1760162515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/10\/2394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,15]]},"references-count":103,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["cancers13102394"],"URL":"https:\/\/doi.org\/10.3390\/cancers13102394","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,15]]}}}